Video
Combination of NAI and BCG found safe, effective in treatment of NMIBC
Author(s):
“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.
Video Player is loading.
In this interview, Karim Chamie, MD, shares interim findings from the ongoing study, “IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer." Chamie is an associate professor of urology at the University of California, Los Angeles.
Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
What a long-term study of patients undergoing RARC reveals about upstaging
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Jason Hafron, MD, predicts coming advancements in bladder cancer
Related Content
